Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Mai 2016 03:01 ET | Quelle: Amaranth Medical, Inc.

Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold in May

MOUNTAIN VIEW, CA , May 18, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, provided a clinical update on its ongoing RENASCENT-II study of its novel APTITUDE™...
18. Mai 2015 15:12 ET | Quelle: Amaranth Medical, Inc.

Amaranth Medical Reports Findings from Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015

Mountain View, CA, May 18, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced plans to report clinical results from the Company's ongoing trial of...
28. Oktober 2013 08:00 ET | Quelle: Amaranth Medical, Inc.

Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE(TM) Bioresorbable Scaffold

MOUNTAIN VIEW, CA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, presented positive six-month angiographic results from its first-in-human study...